Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FLT3 | P36888 | 5/20 | 0.47 |
| ▸ | TOP2A | P11388 | 1/20 | 0.47 |
| ▸ | PAX8 | Q06710 | 1/20 | 0.46 |
| ▸ | RAD52 | P43351 | 3/20 | 0.45 |
| ▸ | UHRF1 | Q96T88 | 1/20 | 0.45 |
| ▸ | NQO2 | P16083 | 3/20 | 0.44 |
| ▸ | CSNK2A1 | P68400 | 1/20 | 0.43 |
| ▸ | NSD2 | O96028 | 1/20 | 0.43 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.43 |
| ▸ | SLC2A1 | P11166 | 1/20 | 0.43 |
| ▸ | NQO1 | P15559 | 1/20 | 0.42 |
| ▸ | TLR9 | Q9NR96 | 1/20 | 0.42 |
| ▸ | NCF1 | P14598 | 2/20 | 0.42 |
| ▸ | ACP1 | P24666 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30089840 | 1.00 | FLT3 (0.47) | FLT3TOP2APAX8RAD52UHRF1 | |
| SCHEMBL21875212 | 0.94 | FLT3 (0.48) | FLT3TOP2ARAD52SCN9ASLC2A1 | |
| SCHEMBL21451071 | 0.89 | MERTK (0.45) | FLT3TOP2ASLC2A1 | |
| SCHEMBL16339164 | 0.88 | MAT2A (0.47) | FLT3TOP2APAX8RAD52UHRF1 | |
| SCHEMBL21875228 | 0.88 | GLA (0.36) | FLT3TOP2APAX8RAD52NQO2 | |
| SCHEMBL30089833 | 0.88 | GLA (0.36) | FLT3TOP2APAX8RAD52NQO2 | |
| SCHEMBL30089850 | 0.87 | PRKCI (0.38) | TOP2ARAD52 | |
| SCHEMBL21875232 | 0.87 | PRKCI (0.38) | TOP2ARAD52 | |
| SCHEMBL21451072 | 0.87 | KDM4E (0.42) | TOP2ARAD52CSNK2A1SCN9ASLC2A1 | |
| SCHEMBL21451010 | 0.86 | HDAC3 (0.36) | FLT3TOP2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-110945001-B | FMS-like tyrosine kinase inhibitors | 硕英生医股份有限公司 | 2022-11-25 | — | — | CN | claimed |
| US-11332476-B2 | Fms-like tyrosine kinase inhibitors | 3SM BIOTRON INC. (TW) | 2022-05-17 | — | — | US | disclosed |
| US-11332476-B2 | Fms-like tyrosine kinase inhibitors | 3SM BIOTRON INC. (TW) | 2022-05-17 | — | — | US | disclosed |
| US-20200131194-A1 | FMS-LIKE TYROSINE KINASE INHIBITORS | Sagabio Co., Ltd. (TW) | 2020-04-30 | — | — | US | disclosed |
| US-20200131194-A1 | FMS-LIKE TYROSINE KINASE INHIBITORS | Sagabio Co., Ltd. (TW) | 2020-04-30 | — | — | US | disclosed |
| WO-2019191896-A1 | FMS-LIKE TYROSINE KINASE INHIBITORS | 3SM BIOTRON INC. (CN) | 2019-10-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11332476-B2 | Fms-like tyrosine kinase inhibitors | FLT3, FLT4, FLT1 | FLT3 1/4885TOP2A 2701/4885PAX8 2417/4885 |
| US-20200131194-A1 | FMS-LIKE TYROSINE KINASE INHIBITORS | FLT3, FLT4, FLT1 | FLT3 1/4885TOP2A 2701/4885PAX8 2417/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.